Caisse DE Depot ET Placement DU Quebec Makes New $23.32 Million Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

Caisse DE Depot ET Placement DU Quebec purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 69,864 shares of the company’s stock, valued at approximately $23,321,000. Caisse DE Depot ET Placement DU Quebec owned about 0.22% of Medpace at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Stone House Investment Management LLC acquired a new stake in Medpace in the 3rd quarter worth approximately $33,000. Ashton Thomas Securities LLC bought a new position in shares of Medpace in the third quarter valued at approximately $37,000. DT Investment Partners LLC acquired a new stake in shares of Medpace in the second quarter worth $41,000. Capital Performance Advisors LLP bought a new stake in shares of Medpace during the 3rd quarter worth $46,000. Finally, Ashton Thomas Private Wealth LLC acquired a new position in Medpace in the 2nd quarter valued at $52,000. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $340.63 on Monday. The stock has a market cap of $10.59 billion, a PE ratio of 29.83, a PEG ratio of 1.88 and a beta of 1.37. The business has a fifty day moving average of $337.82 and a two-hundred day moving average of $370.98. Medpace Holdings, Inc. has a 52-week low of $268.80 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. During the same period last year, the firm posted $2.22 EPS. The business’s revenue was up 8.3% on a year-over-year basis. Analysts predict that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Truist Financial cut their price objective on Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research report on Monday, October 14th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and dropped their price target for the stock from $415.00 to $345.00 in a research report on Wednesday, September 25th. Finally, TD Cowen cut their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $380.56.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.